Sanofi teams with non-profit on a landmark new drug for sleeping sickness
The EMA has offered its endorsement for fexinidazole, which is billed as the first all-oral drug for sleeping sickness.
The Drugs for Neglected Diseases initiative handled the clinical trial work for the drug, with its partners at Sanofi handling the application part. A group of 7 European countries packed the $62.5 million development campaign for the drug, with some added support coming from the Bill & Melinda Gates Foundation and Médecins Sans Frontières.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.